These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Effects of oral physostigmine in Alzheimer's disease. Stern Y; Sano M; Mayeux R Ann Neurol; 1987 Sep; 22(3):306-10. PubMed ID: 3674795 [TBL] [Abstract][Full Text] [Related]
8. Effect of novel arecoline thiazolidinones as muscarinic receptor 1 agonist in Alzheimer's dementia models. Chandra JN; Malviya M; Sadashiva CT; Subhash MN; Rangappa KS Neurochem Int; 2008 Feb; 52(3):376-83. PubMed ID: 17719699 [TBL] [Abstract][Full Text] [Related]
9. Improved verbal learning after outpatient oral physostigmine therapy in patients with dementia of the Alzheimer type. Sevush S; Guterman A; Villalon AV J Clin Psychiatry; 1991 Jul; 52(7):300-3. PubMed ID: 2071560 [TBL] [Abstract][Full Text] [Related]
10. Lisuride treatment of Alzheimer's disease. A preliminary placebo-controlled clinical trial of safety and therapeutic efficacy. Claus JJ; de Koning I; van Harskamp F; Breteler MM; Voet B; Gutzmann H; Dahlke F; van der Cammen T; Hofman A Clin Neuropharmacol; 1998; 21(3):190-5. PubMed ID: 9617511 [TBL] [Abstract][Full Text] [Related]
12. The selective muscarinic agonist xanomeline improves both the cognitive deficits and behavioral symptoms of Alzheimer disease. Bodick NC; Offen WW; Shannon HE; Satterwhite J; Lucas R; van Lier R; Paul SM Alzheimer Dis Assoc Disord; 1997; 11 Suppl 4():S16-22. PubMed ID: 9339268 [TBL] [Abstract][Full Text] [Related]
13. Selegiline in the treatment of Alzheimer's disease: a long-term randomized placebo-controlled trial. Czech and Slovak Senile Dementia of Alzheimer Type Study Group. Filip V; Kolibás E J Psychiatry Neurosci; 1999 May; 24(3):234-43. PubMed ID: 10354658 [TBL] [Abstract][Full Text] [Related]
14. Double-blind crossover study of the cognitive effects of lorazepam in healthy apolipoprotein E (APOE)-epsilon4 carriers. Stonnington CM; Snyder PJ; Hentz JG; Reiman EM; Caselli RJ J Clin Psychiatry; 2009 Oct; 70(10):1379-84. PubMed ID: 19573495 [TBL] [Abstract][Full Text] [Related]
15. Effectiveness and safety of velnacrine for the treatment of Alzheimer's disease. A double-blind, placebo-controlled study. Mentane Study Group. Antuono PG Arch Intern Med; 1995 Sep; 155(16):1766-72. PubMed ID: 7654110 [TBL] [Abstract][Full Text] [Related]
16. Effects of donepezil on verbal memory after semantic processing in healthy older adults. FitzGerald DB; Crucian GP; Mielke JB; Shenal BV; Burks D; Womack KB; Ghacibeh G; Drago V; Foster PS; Valenstein E; Heilman KM Cogn Behav Neurol; 2008 Jun; 21(2):57-64. PubMed ID: 18541979 [TBL] [Abstract][Full Text] [Related]
17. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting. Tariot PN; Cummings JL; Katz IR; Mintzer J; Perdomo CA; Schwam EM; Whalen E J Am Geriatr Soc; 2001 Dec; 49(12):1590-9. PubMed ID: 11843990 [TBL] [Abstract][Full Text] [Related]
18. A neuropsychological test battery for use in Alzheimer disease clinical trials. Harrison J; Minassian SL; Jenkins L; Black RS; Koller M; Grundman M Arch Neurol; 2007 Sep; 64(9):1323-9. PubMed ID: 17846273 [TBL] [Abstract][Full Text] [Related]